Nurix Therapeutics, Inc. $NRIX Shares Acquired by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Nurix Therapeutics by 2.0%, now holding approximately 3.19% of the company, valued at $28.8 million.
• Insider sales saw Gwenn Hansen and CFO Houte Hans Van reduce their holdings by 5.87% and 13.20% respectively, selling a combined total of shares valued at over $111,000.
• Narix Therapeutics reported a quarterly earnings per share (EPS) of ($0.52), outperforming analysts' estimates, and has received multiple analyst ratings ranging from "buy" to "hold".

T. Rowe Price Investment Management Inc. boosted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 2.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,428,283 shares of the company's stock after buying an additional 47,855 shares during the quarter. T. Rowe Price Investment Management Inc. owned 3.19% of Nurix Therapeutics worth $28,849,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in Nurix Therapeutics during the fourth quarter worth about $28,000. Aquatic Capital Management LLC purchased a new position in Nurix Therapeutics during the fourth quarter worth about $87,000. BNP Paribas Financial Markets purchased a new position in Nurix Therapeutics during the fourth quarter worth about $164,000. Exchange Traded Concepts LLC boosted its stake in Nurix Therapeutics by 38.9% during the first quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock worth $109,000 after buying an additional 2,562 shares during the period. Finally, E Fund Management Co. Ltd. purchased a new position in Nurix Therapeutics during the first quarter worth about $122,000.

Nurix Therapeutics Price Performance

Shares of NRIX traded down $0.14 during midday trading on Tuesday, reaching $9.53. The stock had a trading volume of 620,553 shares, compared to its average volume of 684,601. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $29.56. The company's fifty day simple moving average is $11.33 and its two-hundred day simple moving average is $11.93. The company has a market cap of $728.57 million, a price-to-earnings ratio of -3.65 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. The business had revenue of $44,056 billion for the quarter, compared to analyst estimates of $16.26 million. On average, sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,402 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $11.03, for a total transaction of $59,584.06. Following the sale, the chief financial officer owned 35,512 shares of the company's stock, valued at approximately $391,697.36. This trade represents a 13.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gwenn Hansen sold 4,308 shares of the firm's stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total transaction of $51,739.08. Following the sale, the insider directly owned 69,023 shares in the company, valued at approximately $828,966.23. The trade was a 5.87% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,014 shares of company stock worth $163,014. 7.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on NRIX. Stephens reaffirmed an "overweight" rating and set a $30.00 target price on shares of Nurix Therapeutics in a research note on Thursday, July 10th. UBS Group reduced their price target on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, July 10th. Morgan Stanley set a $16.00 price target on shares of Nurix Therapeutics and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Wall Street Zen raised shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. Finally, Oppenheimer reissued an "outperform" rating and set a $30.00 price target (down previously from $32.00) on shares of Nurix Therapeutics in a research report on Thursday, July 31st. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.87.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.